A AB BS S T TR RA AC CT T O Ob b j je ec c t ti i v ve e: : Pe ro xi so me pro li fe ra tor-ac ti va ted re cep tor gam ma (PPARγ), li pids, li pop rote ins, and adi po ki nes ha ve re cently be en shown to be as so ci a ted with psychi at ric di se a ses. Our ma jor aim is to in ves ti ga te the con tri bu ti on of the PPARγ ge ne poly morp hism, adi po ki nes, li pids, and li popro te ins to the de ve lop ment of ma jor dep res si on. M Ma a t te e r ri i a al l a an nd d M Me et t h ho od ds s: : The fre qu ency of Pro12Ala in exon 2 and C478T in exon 6 of the PPARγ ge ne, li pids and adi po ki nes in ma jor dep res si on (n = 78) and con trol sub jects (n= 64) we re analy zed. Ge noty pes of PPARγ ge ne poly morp hisms we re exa mined. Se rum lep tin, adi po nec tin, and re sis tin we re stu di ed by enz yme-lin ked im mu no sor bent as say (ELI SA). Se rum apo A1, apo B, and Lp(a) le vels we re de ter mi ned by im mu no nep he lo metry. Se rum total cho les te rol, trigl yce ri de, HDL-cho les te rol and LDL-cho les te rol le vels we re analy zed by enz ymatic met hods. R Re e s su ul lt ts s: : The ge noty pes of exon 2 and exon 6 dis tri bu ti on did not dif fer bet we en the con trol sub jects and patients with ma jor dep res si on. Fre qu en ci es of ge noty pes of Pro12Ala, and Ala12Ala in exon 2 in over we ight and obe se pa ti ents with ma jor dep res si on we re hig her than tho se of over we ight and obe se con trols. C478T poly morp hism was hig hest in over we ight and obe se pa tients with ma jor dep res si on. Pro12Ala and Ala12Ala ge noty pes in exon 2 of PPARγ ge ne in pa ti ents we re fo und to be as so ci a ted with trigl yce ri de and HDL-cho les te rol. The re we re sig ni fi cant dif fe rences re gar ding glu co se, to tal cho les te rol, LDL-cho les te rol, apo B, Lp(a), adi po nec tin and re sis tin le vels bet we en pa ti ent and con trol sub jects. C Co on nc c l lu u s si i o on n: : PPARγ exon ge ne poly morp hisms, al te ra ti ons in lipid pro fi le and adi po ki nes may be as so ci a ted with the de ve lop ment of ma jor dep res si on.
a jor dep res si on (MD) is a di sor der of emo ti on cha rac te ri zed by per sis tent sad mo od or a loss of in te rest or ple a su re in da ily ac ti vi ti es and by a num ber of as so ci a ted symptoms, such as we ight loss or ga in, loss of ap peti te, sle ep dis tur ban ce, psycho mo tor re tar da ti on, fa ti gu e and fe e lings of gu ilt. 1 Pa ti ents with re current type ma jor dep res si ve di sor der had lo wer qua lity of li fe in terms of physi cal func ti o ning, ge ne ral he alth per cep ti on, and physi cal com po nent sum mary sco re compared to pa ti ents with sing le epi so de type ma jor dep res si ve di sor der. 2 Pe ro xi so me pro li fe ra tor-ac ti va ted re cep tor gam ma (PPARγ) is an im por tant trans crip ti on factor that re gu la tes li pid and glu co se me ta bo lisms. 3 Thre e types of PPAR ha ve be en des cri bed up to date, and of the se, PPARγ has be en shown to re gu la te adi pocy te dif fe ren ti a ti on and li pid me ta bolism thro ugh the ac ti va ti on of adi pocy te-spe ci fic ge nes. . 4 The PPARγ re gu la tes the trans crip ti on of tar get ge nes pro te in by for ming a he te ro di mer with the re ti no id X re cep tor which then binds to spe ci fic PPARγ res pon se ele ments in the pro mo ter re gi ons of the se ge nes. 5 For ced ex pres si on of PPARγ le ads to the dif fe ren ti a ti on of adi pocy tes in fib rob lasts. . 6 Do mi nant ne ga ti ve mu tant PPARγ al le les that im pa ir PPARγ func ti on ha ve pro vi ded in sight in to its bi o lo gi cal func ti on in vi vo. A Pro115Gln PPARγ mu tant has been re por ted to be re la ted to ex ces si ve adi po se tis su e ac cu mu la ti on thro ugh an in trin sic in cre a se in adi po ge nic ac tivity. 7 Mu ta ti ons in hu man PPARγ have been asso ci a ted with se ve re in su lin re sis tan ce, hyperten si on, di a be tes mel li tus and al te ra ti ons in li pid pro fi le, such as low le vels of high-den sity li pop rote in cho les te rol and high le vels of trigl yce ri des. 8 The re are thre e PPARγ mRNA iso forms, PPARγ1, γ2, and γ3, ge ne ra ted by al ter na ti ve pro mo ter regi ons. PPARγ1 mRNA is fo und in va ri ab le amounts in all tis su es, such as he art, li ver, ske le tal musc le and adi po se tis su e. PPARγ2 is ex pres sed in adi po se tis su e and li ver whe re as PPARγ3 is con fined to mac rop ha ges, co lon epit he li um, and adi pose tis su e.
9,10 PPAR γ2 con ta ins 30 ad di ti o nal ami no acids at its N-ter mi nus and may con fer a gre a ter li gand-in de pen dent ac ti va ti on func ti on upon this iso form. PPARγ2 ex pres si on is in cre a sed in adi pose tis su e ta ken from obe se sub jects, but ex pres si on in the le an sub jects is re du ced du ring we ight loss.
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A num ber of ge ne tic va ri ants in the PPARγ ge ne ha ve be en re por ted. The Pro12Ala poly morp hism in PPARγ2 was first iden ti fi ed in 1997, 12 and the ra re al le le fre qu en ci es are ap pro xi ma tely 12% in Ca u ca si ans, 10% in Na ti ve Ame ri cans, 8% in Samo ans, 4% in Ja pa ne se, 3% in Af ri can-Ame ri cans, 2% in Na u ru ans, and 1% in Chi ne se. 13 At po si ti on 34, CCA-to-GCA mis sen se mu ta ti on ca u ses an ami no acid chan ge from a pro li ne to an ala ni ne at co don 12 (Pro12Ala). This exon en co des the NH 2 -ter mi nal re si du e that de fi nes the adi pocy te-spe cific PPARγ2 iso form. Func ti o nal dif fe ren ces are ob ser ved for this Ala va ri ant. The se dif fe ren ces indi ca te that Ala va ri ant has a re du ced af fi nity for the res pon se ele ment and a lo wer ca pa city for acti va ting tar get ge nes. 14 Whi le it has long be en ap pa rent that obe sity is a ma jor risk fac tor for MD, it has re cently be en ap pre ci a ted that adi po se tis su e, in ad di ti on to its role as an energy re ser vo ir, mo du la tes energy me tabo lism vi a sec re ti on of cir cu la ting adi pocy to ki nes. The re sis tin, lep tin, and adi po nec tin, which are iden ti fi ed as adi po kins, ap pe ar to be im por tant in re gu la ting in su lin sen si ti vity. Obe sity, par ti cu larly vis ce ral obe sity, is as so ci a ted with in su lin re sis tance, 15 but the mec ha nism whe reby adi po se tis su e mo du la tes in su lin sen si ti vity is con tro ver si al. 16 Re sis tin is a pro te in pro du ced by ma tu re adipocy tes which re gu la tes who le-body in su lin sen siti vity. It is ma inly ex pres sed in vis ce ral whi te fat. It was ini ti ally iso la ted as an mRNA who se ex pres si on is sup pres sed in res pon se to ro sig li ta zo ne, PPARγ ago nist that en han ces in su lin sen si ti vity. 16 Lep tin re gu la tes the ba lan ce bet we en fo od inta ke and energy ex pen di tu re. The plas ma lep tin levels are cor re la ted with the to tal body fat mass. 17 Ba sal con cen tra ti ons of lep tin in the blo ods tre am are pro por ti o nal to adi po se tis su e mass and hen ce lep tin le vel is con si de red as a go od mar ker of adipo se tis su e si ze. 18 Adi po nec tin is an adi pocy te-spe ci fic pro te in that sen si ti zes the li ver and musc le to the ac ti on of in su lin. It has be en re por ted that plas ma adi po necTurkiye Klinikleri J Med Sci 2011;31 (5) tin is lo wer in obe se sub jects compared to le an subjects, lo wer in di a be tic pa ti ents compared to nondi a be tic pa ti ents, and is ne ga ti vely cor re la ted with body we ight, vis ce ral fat mass, and res ting in su lin le vel. Adi po nec tin le vels in the cir cu la ti on are upre gu la ted by the PPARγ ago nists such as ro sig li tazo ne. 19 Un for tu na tely, the re no stu di es up date have investigated whet her poly morp hisms in PPARγ2 ge ne are as so ci a ted with ma jor dep res si on or not. The pur po se of this study is to find known polymorp hisms of PPARγ2 in MD, to me a su re se rum lep tin, adi po nec tin, re sis tin, li pid and li pop ro te in le vels, and to de ter mi ne whether there are associations among PPAR poly morm hisms and adi po kines.
MATERIAL AND MET HODS

STUDY SET TING AND PO PU LA TI ONS
The study was car ri ed out in the De part ments of Bi oc he mistry and Psychi atry in Fa culty of Me di cine, Ka ra de niz Tech ni cal Uni ver sity. The study was ap pro ved by the lo cal et hics com mit te e and in formed con sents we re ob ta i ned from the par ti ci pants af ter all pro ce du res we re fully exp la i ned. The pa tients bet we en 18 and 65 ye ars of age who ac cep ted to par ti ci pa te in the study by sig ning up the in formed consent forms we re inc lu ded in the study. The ones who had psycho tic di sor der or de men ti a, had a his tory of psychi at ric di sor der ex cept ma jor depres si on or used psychtro pic drugs we re exc lu ded from the study. In the psychi at ric exa mi na ti ons of the pa ti ents and the con trol gro up, Struc tu red Clini cal In ter vi ew for the Di ag nos tic and Sta tis ti cal Ma nu al of Men tal Di sor ders IV (DSM-IV) was used. 2 The con trol gro up was de ri ved from the hospi tal staff and the ir re la ti ves without any his tory of se ve re so ma tic di se a se or psychi at ric di sor der and ac cep ted to par ti ci pa te in the study vo lun ta rily after be ing in for med abo ut the aim of the study. Pati ent and con trol sub jects we re in cor po ra ted in to the study fol lo wing the exa mi na ti on of the ir medi cal his to ri es. In di vi du als who we re on me di ca tion (such as an ti di a be tics, an tihy per ten si ve, an ti li pi de mics etc.) du e to di a be tes mel li tus type 2, car di o vas cu lar di se a se and ot her chro nic di se a ses we re exc lu ded. Seventy eight pa ti ents di ag no sed with ma jor dep res si on and 64 he althy controls were included in the study. All inc lu ded pa ti ents and vo lun te ers comp le ted the study. Age, gen der, and body mass index (BMI) of the all sub jects we re recor ded. Pa ti ent gro up was di vi ded in to three groups with re gard to BMI: (< 18.5 kg/m 2 for le an, 18.5-24.9 kg/m 2 for nor mally we igh ted, > 25 kg/m 2 for over we ight and obe se). The re we re 31 over weight and obe se, 24 nor mal we igh ted, 23 le an pa tients. The con trol gro up was al so di vi ded in to three gro ups; 22 over we ight and obe se, 20 nor mal weigh ted, and 22 le an. Af ter an over night fas ting peri od, pe rip he ral ve no us blo od samp les of the sub jects we re drawn in to the tu bes. Se rum to tal cho les te rol, trigl yce ri de, HDL-cho les te rol, LDLcho les te rol le vels we re analy zed by enz yma tic methods using Roc he Di ag nos tics Mo du lar DP analy tic system (Ger many). Se rum Apo A1, apo B, and Lp(a) le vels we re de ter mi ned by im mu no nep he lo metry (Da de Beh ring, BN II). Se rum lep tin le vels we re me a su red by Enz yme-lin ked Im mu no met ric As say (ELI SA) kit (ca ta log no: KAP2281, Bi o So ur ce Inter na ti o nal Inc., USA). Se rum re sis tin and adi ponec tin le vels we re me a su red with ELI SA kits ac cor ding to the ma nu fac tu rer's ins truc ti ons (respec ti vely, ca ta log no: ER1001-1, ca ta log no: EA2500-1, As say Pro, USA).
Phe noty pic cha rac te ris tics we re de ter mi ned.
DNA EX TRAC TI ON, PCR AND DNA SE QU EN CING OF PPARα2 EXON 2 AND EXON 6
Pro12Ala in exon 2 and C1431T in exon 6 of the PPARγ ge ne we re scre e ned for the pre sen ce of poly morp hisms in a to tal of 142 in di vi du als. DNA was ex trac ted from who le blo od samp les by using In vi sorb Spin Blo od Mi ni Kit (Ca ta log no: 1031100200; Ber lin, Ger many). So me DNA ex tracti ons ha ve be en fa i led for exon 6 (fi ve sub jects in MD gro up and one con trol sub ject). Amp li fi ca ti ons of the PPAR γ2 exon 2 and exon 6 we re per for med with Amp li Taq Gold® PCR Mas ter Mix (2X) (Appli ed Bi osy stems, Ca li for ni a, USA) using fol lo wing pri mers: 5'-CCA GA A A AT GA CA GACC TCA GA -CA-3' and 5'-CA GA A TAGT GCA ACT GGA A GA -AGG-3' for exon 6.5'-GATGTC TTGACT CAT-GGG-3' and 5'-GGA A GA CA A AC TA CA A GAGC-3' for exon 2. The re ac ti ons we re per for med with an ini ti al de na tu ring cycle of 10 mi nu tes at 95°C, fol lowed by 30 cycles of 95°C for 45s, 58°C for 60s, 72°C for 60 s, and a 7 mi nu tes fi nal ex ten si on at 72°C. BigD ye Cycle Se qu en cıng v3.1 Kit (App li ed Bi osystems, Ca li for ni a, USA) was used for cycle se qu encing re ac ti ons. Cycle se qu en cing was per for med for 25 cycles of 96 °C for 10 s, 50 °C for 5 s, and 60 °C for 4 min on Ge ne Amp PCR Systems 9700 (App lied Bi osy stems, Ca li for ni a, USA) and se qu en cing pro ducts we re pu ri fi ed using SEP HA DEX G-50 (Sig ma-Al drich, Ta uf kirc hen, Ger many). Au to mated se qu en cing was car ri ed out on an ABI PRISM 310 Ge ne tic Analy zer (App li ed Bi osy stems, Ca lifor ni a, USA). Se qu en cing analy sis was per for med with SeqS ca pe v2.6 soft wa re (App li ed Bi osy stems, Ca li for ni a, USA) and Bi o E dit (Bi o E dit, Carl sbad, CA) soft wa re using mu ta ti on charts.
CC ge noty pes ex pres sed in C478T poly morphism in exon 6 were eva lu a ted as wild type, whi le TC was he te rozy go us and TT was ho mozy go us mutant. For Pro12Ala poly morp hism in exon 2, CC was re ve a led as wild type, GC was he te rozy go us and GG as ho mozy go us mu tant.
DA TA ANALY SIS
The re sults we re ex pres sed as me an ± SD. Dis tribu ti on of va ri ab les in the study gro ups was as sessed by Kol mo go rov Smir nov test. Com pa ri sons of cli ni cal pa ra me ters for pa ti ent and con trol gro ups we re do ne by eit her un pa i red t-test (nor mal distri bu ti on) or Mann-Whit ney-U test (not nor mal dis tri bu ti on). The pa ra me ters ac cor ding to subgro ups (over we ight and obe se, nor mal and le an) wit hin nor mal dis tri bu ti on we re analy zed by post hoc Tu key test af ter one way ANO VA test, those not wit hin nor mal dis tri bu ti on by Krus kal Wal lis test. The dis tri bu ti on of al le les and ge noty pes bet we en gro ups was com pa red using χ 2 analy sis test. A va lu e of p < 0.05 was con si de red sig ni fi cant.
RE SULTS
Se rum glu co se, to tal cho les te rol, LDL-cho les te rol, apo B, Lp(a), adi po nec tin, and re sis tin le vels of the pa ti ents with MD we re fo und sig ni fi cantly hig her compared to tho se of the con trol gro up (Tab le 1).
Tab le 2 shows cli ni cal pa ra me ters wit hin subgro ups (over we ight and obe se, nor mal, le an).Gluco se, to tal cho les te rol, trigl yce ri des, LDL-cho les- a te rol, apo B and lep tin le vels had the hig hest le vels in over we ight and obe se pa ti ents with MD, whe reas HDL-C le vels we re the lo west.
The ge noty pes of exon 2 and exon 6 dis tri buti on did not dif fer bet we en the con trol gro up and the pa ti ents with MD (Tab le 3).
The fre qu en ci es of Pro12Ala (CG), and Ala12Ala (GG) ge noty pes in exon 2 in over we ight and obe se ma jor dep res si ve pa ti ents we re hig her than tho se of over we ight and obe se con trols (Table 4), but the re was no sig ni fi cant dif fe ren ce.
The fre qu en ci es of exon 6 ge noty pes of ma jor dep res si ve pa ti ents did not dif fer from tho se of the con trol gro up. Ho we ver, T al le le had the hig hest fre qu ency in over we ight and obe se pa ti ents with MD (Tab le 4). Pro12Ala (CG) and Ala12Ala (GG) poly morphisms in exon 2 of PPARγ ge ne we re fo und to be as so ci a ted with li pids (in cre a sed trigl yce ri des and dec re a sed HDL-C) (Tab le 5), whe re as poly morphisms in exon 6 we re not fo und to have such an association.
DIS CUS SI ON
PPARγ plays an im por tant ro le in the con trol of adi pocy te dif fe ren ti a ti on and in the re gu la ti on of li pid and glu co se ho me os ta sis. The re fo re, the PPARγ ge ne may re gu la te in su lin sen si ti vity and re sis tan ce. 20 Swar brick et al. analy zed the re la ti ons hip bet we en Pro12Ala poly morp hism of the PPARγ ge ne and com bi ned hyper li pi d e mi a in obe se pa ti ents.
Turkiye Klinikleri J Med Sci 2011;31 (5) The re we re sig ni fi cant dif fe ren ces in the PPARγ2 Pro12Ala poly morp hism and al le le in li pid pro fi le in obe se car ri ers.
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Me mi sog lu et al. stu di ed the re la ti ons hips bet we en PPARγ Pro12Ala ge noty pe and BMI ac cording to di e tary fat in ta ke. They pro po sed that the re la ti ons hip bet we en di e tary fat in ta ke and plas ma li pid con cen tra ti ons dif fered ac cor ding to PPARγ ge noty pe. The ir fin dings sug gest that plas ma to tal and HDL-cho les te rol le vels may ne ed to be ta ken in to ac co unt in PPARγ ge noty pe analy sis. 21 Tai et al. in ves ti ga ted the as so ci a ti on of C1431T and Pro12Ala poly morp hisms at the PPARγ lo cus with plas ma li pids and in su lin re sis tan ce-re la ted vari ab les, ac cor ding to di a be tes sta tus, in an Asi an popu la ti on. They fo und a dec re a sed risk of di a be tes in car ri ers of the T al le le of the C1431T poly morp hism in exon 6 of the PPARγ ge ne in the who le Sin ga poTurkiye Klinikleri J Med Sci 2011;31 (5) 1070 Aliyazıcıoğlu ve ark.
Tıbbi Biyokimya
Major depressive patients Control groups
Genotype overweight and obese n % normal n % lean n % overweight and obese n % normal n % lean n % re an po pu la ti on, and that was stron ger in In di ans. Con ver sely, this as so ci a ti on was not fo und for the Pro12Ala poly morp hism. The se ob ser va ti ons sugges ted that this va ri ant co uld be a mar ker for a re le vant func ti o nal mu ta ti on. 22 We tri ed to show an as so ci a ti on bet we en PPAR ge ne poly morp hism and MD, two emtities that had be en fo und to be as so ci a ted with obesity. 23 In the pre sent study, there was no evi den ce suggesting Pro12Ala (CG) poly morp hism as a predis po sing fac tor for MD. In addition, al le le fre quen ci es we re si mi lar in the obe se and le an pa ti ents. However, dif fe ren ces we re ob ser ved bet we en poly morp hic ge noty pes (CG + GG) for trigl yce ride and HDL-cho les te rol in ma jor dep res si ve pa tients com pa red to nor mal ge noty pes (CC). Val ve et al. fo und that Ala12Ala ge noty pe was as so ci a ted with in cre a sed BMI, fat mass, and wa ist and hip cir cum fe ren ces when com pa red to obe se wo men (n = 141) with the Pro12Ala or Pro12Pro ge notypes. 24 De eb et al. (n = 973) fo und that Ala/Ala indi vi du als had con si de rably hig her HDL cho les te rol and lo wer trigl yce ri de con cen tra ti ons on fol low-up than did Pro/Pro and Pro/Ala pa tients. 25 Swar brick et al. sho wed that obe se Pro/Ala and Ala/Ala pa ti ents had lo wer con cen tra ti ons of HDL-cho les te rol and a trend to ward hig her concen tra ti ons of trigl yce ri des than did obe se Pro/Pro pa ti ents. 11 In vit ro stu di es ha ve shown that the Ala12 vari ant of the PPARγ ge ne is less ef fec ti ve for ac ti vating tar get ge nes, one of which is the li pop ro te in li pa se (LPL) ge ne. Both chylo mic rons and VLDLs are ini ti ally me ta bo li zed by LPL, which hydrolyzes trigl yce ri des, re le a sing fatty acids, chylo mic ron rem nants, and LDL cho les te rol. Al te ra ti ons in the blo od li pid pro fi le are se en in he te rozy go us li popro te in li pa se de fi ci ency, an ef fect which is mo re pro no un ced in obe se in di vi du als.
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In Me ir ha eg he et al's. study (n = 839), poly morp hic al le les we re as so ci a ted with in cre a sed body weight, BMI, wa ist cir cum fe ren ce and an at he ro ge nic li pid pro fi le. 26 The ir re sults we re si mi lar to our findings, but li pid as so ci a ti on inc lu ded cho les te rol and its de ri va ti ve (LDL-C) as well. They sug gest that gene tic va ri a bi lity of PPARγ2 af fects body we ight control and li pid ho me os ta sis in hu mans. On the ot her hand, they do not sup port a sig ni fi cant ro le for the PPARγ2 Pro12Ala poly morp hism in the e ti o logy of non-in su lin-de pen dent di a be tes mel li tus. Se ve ral stu di es sug gest that PPARγ has a di rect ef fect on leptin ge ne trans crip ti on. For ins tan ce, the phar ma colo gi cal ac ti va ti on of PPARγ by thi a zo li di ne di o nes in ani mal mo dels and in cell cul tu re stu di es re sults in down-re gu la ti on of lep tin ge ne ex pres si on. 27, 28 Meir ha eg he et al. sho wed that va ri a bi lity wit hin the PPARγ ge ne lo cus in obe se sub jects was as so ci a ted with cir cu la ting lep tin le vels and might mo dify the re la ti ons hips bet we en lep tin le vels and adi po se tissu e mass. 26 In our study, se rum lep tin le vels of the le an and nor mal we ight pa ti ents we re lo wer than the over we ight and obe se pa ti ents (p< 0.05). Furt her epi de mi o lo gi cal and ge ne tic stu di es of the PPARγ ge ne poly morp hisms are ne e ded to im pro ve our un ders tan ding of the comp lex re gu la tory mec hanisms go ver ning lep tin ex pres si on by adi pocy tes and the ir im por tan ce in obe sity.
Re sis tin has be en pro po sed to be a con nec ting link bet we en obe sity and in su lin re sis tan ce in rodents. 29 Although se ve ral stu di es ha ve in ves ti ga ted its ro le in MD 30 and obe sity, 31 the re are not many re ports in re la ti on to MD. . In this study, we in ves tiga ted the ef fect of Pro12Ala and C478T SNPs on plas ma re sis tin le vels in ma jor dep res si ve di sor ders. Alt ho ugh hig her le vels of re sis tin ha ve be en recently fo und to be po si ti vely as so ci a ted with in sulin re sis tan ce, 32 we did not ob ser ve any dif fe ren ce in re sis tin le vels in sub jects clas si fi ed ac cor ding to BMI. Ha se eb et al. sho wed that plas ma re sis tin le vels we re not as so ci a ted with me ta bo lic syndro me. They fo und that the C1431T SNP was as so ci a ted with hig her le vels of plas ma re sis tin. 33 
CONC LU SI ON
Poly morp hisms fo und in the pre sent study we re not as so ci a ted with MD. On the other hand, , in sig ni ficant dif fe ren ces may be du e to a small number of pattients and al so small number of pa ti ents in the sub gro ups. Only 7% of obe se pa ti ents ha d ho mozygo us SNP (Ala12Ala), whi le over we ight and obe se sub jects in con trol gro up did not ha ve it at all. All the adi po ki nes and li pid pa ra me ters we re fo und to be as so ci a ted for MD pa ti ents, es pe ci ally for overwe ight and obe se pa ti ents with MD.
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